FOR IMMEDIATE RELEASE
LUNGevity Foundation awards six grants to outstanding researchers for significant lung cancer research projects; additional awards to be announced later this year
WASHINGTON, DC (July 30, 2013) – LUNGevity Foundation, which supports the largest grant awards program of any lung-cancer focused organization in the U.S., announced that it has awarded $900,000 in new lung cancer research funds to six exceptional researchers through its Career Development and Targeted Therapeutics Awards programs. The work of these researchers will help ensure continued progress against this cancer that kills more people than the next four cancers combined. In addition to these awards, LUNGevity will announce funding for awards through its Early Detection Awards program later this year as well as provide $500,000 of funding to support ongoing projects. This will bring the year’s funding total to $1.8 million. LUNGevity’s Career Development Awards for Translational Research program identifies future research leaders who will keep the field of lung cancer research vibrant with new ideas. 2013 Career Development Awards for Translational Research were made to:
LUNGevity’s Targeted Therapeutics for Translational Research program supports the discovery and validation of biomarkers or novel targeted therapeutics that will make a difference in the clinical treatment and survival of patients. 2013 Targeted Therapeutics Awards for Translational Research were made to:
“Lung cancer, which will kill about 160,000 people this year, accounts for 27% of cancer deaths in the United States, yet less than 6% of federal cancer research funding is allocated toward it. The translational research funding that LUNGevity provides is critical in helping to make up for this disparity. This year’s award winners, selected after a rigorous review process, will move us forward toward the breakthroughs that will make an important difference not just to survivorship but also to the quality of survivorship,” said Andrea Ferris, President and Chairman of LUNGevity Foundation.
Second-year funding for ongoing projects includes continued support for the following Career Development Award for Translational Research projects in early detection and targeted therapeutics:
Special thanks to Genentech and our other donors for supporting the LUNGevity Scientific Research Program.
The Foundation works with its Scientific Advisory Board, eighteen prominent and leading scientists and researchers, and additional experts to ensure that grants are awarded to the proposals with the greatest potential for saving lives. Under the guidance of the Advisory Board, chaired by Dr. Pierre Massion, Associate Professor of Medicine and Cancer Biology in the Division of Allergy, Pulmonary and Critical Care Medicine at Vanderbilt University Medical Center, LUNGevity has become the nation’s premier private grant-making organization funding research for the early detection and effective treatment of lung cancer.
About LUNGevity Foundation
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support and education for all those affected by the disease.
Our vision is a world where no one dies of lung cancer.
For more information about the grants or LUNGevity Foundation, please visit www.LUNGevity.org.
About Lung Cancer